Sol-Gel Technologies Ltd. (SLGL)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $68.18
- As of
Kresmion compiles this page from SLGL's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Sol-Gel Technologies Ltd. (SLGL): 2 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 6-K filed 2026-10-06.
See the full SLGL dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for SLGL on one page. Preview it with sample data, then open it live with a free account.
Preview the SLGL dossierActive events for SLGL
- mediumEarnings above estimates
Q2-2026: Beat consensus by 52.0%, EPS $-1.13 vs $-2.3562 estimate
- high13F: large increase
CITADEL ADVISORS LLC added +430% to SLGL (2026Q2)
- medium13F: new position
MILLENNIUM MANAGEMENT LLC new position in SLGL
- mediumEarnings above estimates
Q3-2024: Beat consensus by 92.5% - EPS $-0.1 vs $-1.326 estimate
- mediumEarnings above estimates
Beat consensus by 92.5% - EPS $-0.1 vs $-1.326 estimate
FREE, NO ACCOUNT
Every event on SLGL, as it fires
You are seeing 5 of 7 events recorded on SLGL since 2026-06-02.
The five above landed across 4 days. The other 2 were recorded on those same days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in SLGL (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP M8694L137 · 2026Q2 | $2.4M | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP M8694L137 · 2026Q2 | $248K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, SLGL
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 20-FSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
SLGL against its peers
SLGL's operating margin of -38.9% ranks in the 75th percentile of 13 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | SLGL | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 19.4M USD | 6.6M USD | 59 | 15 |
| Revenue YoY | 68.0% | n/a | n/a | 2 |
| Operating margin | -38.9% | -741.3% | 75 | 13 |
| Net margin | -31.6% | -557.8% | 70 | 14 |
| Return on equity | -26.9% | -65.8% | 73 | 23 |
Peers (24): LXEO, IFRX, LYEL, PALI, IKT, GLSI, KROS, ZNTL, ACIU, IMRX, VNDA, BBOT, LRMR, BCYC, CABA, CAMP, OCGN, RCKT, QTTB, ABEO, PLX, FATE, LCTX, ALEC. Left out: VCRE (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (SLGL: 20-F), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow SLGL on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to SLGL for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.